GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Lux Health Tech Acquisition Corp (NAS:LUXA) » Definitions » ROE %

Lux Health Tech Acquisition (Lux Health Tech Acquisition) ROE % : 5.73% (As of Jun. 2022)


View and export this data going back to 2020. Start your Free Trial

What is Lux Health Tech Acquisition ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Lux Health Tech Acquisition's annualized net income for the quarter that ended in Jun. 2022 was $18.76 Mil. Lux Health Tech Acquisition's average Total Stockholders Equity over the quarter that ended in Jun. 2022 was $327.45 Mil. Therefore, Lux Health Tech Acquisition's annualized ROE % for the quarter that ended in Jun. 2022 was 5.73%.

The historical rank and industry rank for Lux Health Tech Acquisition's ROE % or its related term are showing as below:

LUXA's ROE % is not ranked *
in the Diversified Financial Services industry.
Industry Median: 0.54
* Ranked among companies with meaningful ROE % only.

Lux Health Tech Acquisition ROE % Historical Data

The historical data trend for Lux Health Tech Acquisition's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lux Health Tech Acquisition ROE % Chart

Lux Health Tech Acquisition Annual Data
Trend Dec20 Dec21
ROE %
- 8.91

Lux Health Tech Acquisition Quarterly Data
Aug20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22
ROE % Get a 7-Day Free Trial 2.60 3.39 6.17 9.45 5.73

Competitive Comparison of Lux Health Tech Acquisition's ROE %

For the Shell Companies subindustry, Lux Health Tech Acquisition's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lux Health Tech Acquisition's ROE % Distribution in the Diversified Financial Services Industry

For the Diversified Financial Services industry and Financial Services sector, Lux Health Tech Acquisition's ROE % distribution charts can be found below:

* The bar in red indicates where Lux Health Tech Acquisition's ROE % falls into.



Lux Health Tech Acquisition ROE % Calculation

Lux Health Tech Acquisition's annualized ROE % for the fiscal year that ended in Dec. 2021 is calculated as

ROE %=Net Income (A: Dec. 2021 )/( (Total Stockholders Equity (A: Dec. 2020 )+Total Stockholders Equity (A: Dec. 2021 ))/ count )
=27.097/( (290.416+317.514)/ 2 )
=27.097/303.965
=8.91 %

Lux Health Tech Acquisition's annualized ROE % for the quarter that ended in Jun. 2022 is calculated as

ROE %=Net Income (Q: Jun. 2022 )/( (Total Stockholders Equity (Q: Mar. 2022 )+Total Stockholders Equity (Q: Jun. 2022 ))/ count )
=18.76/( (325.108+329.797)/ 2 )
=18.76/327.4525
=5.73 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Jun. 2022) net income data. ROE % is displayed in the 30-year financial page.


Lux Health Tech Acquisition  (NAS:LUXA) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Jun. 2022 )
=Net Income/Total Stockholders Equity
=18.76/327.4525
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(18.76 / 0)*(0 / 345.538)*(345.538 / 327.4525)
=Net Margin %*Asset Turnover*Equity Multiplier
=N/A %*0*1.0552
=ROA %*Equity Multiplier
=N/A %*1.0552
=5.73 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Jun. 2022 )
=Net Income/Total Stockholders Equity
=18.76/327.4525
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (18.76 / 18.896) * (18.896 / -1.876) * (-1.876 / 0) * (0 / 345.538) * (345.538 / 327.4525)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 0.9928 * -10.0725 * N/A % * 0 * 1.0552
=5.73 %

Note: The net income data used here is four times the quarterly (Jun. 2022) net income data. The Revenue data used here is four times the quarterly (Jun. 2022) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Lux Health Tech Acquisition ROE % Related Terms

Thank you for viewing the detailed overview of Lux Health Tech Acquisition's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Lux Health Tech Acquisition (Lux Health Tech Acquisition) Business Description

Traded in Other Exchanges
N/A
Address
920 Broadway, 11th Floor, New York, NY, USA, 10010
Lux Health Tech Acquisition Corp is a blank check company.
Executives
Frederic H Moll director C/O INTUITIVE SURGICAL INC, 950 KIFER ROAD, SUNNYVALE CA 94086
Joshua Defonzo director, officer: Chief Executive Officer 1500 CORDILLERAS AVENUE, SAN CARLOS CA 94070
Peter Hebert director, 10 percent owner C/O LUX VENTURES, 295 MADISON AVE, 24TH FLOOR, NEW YORK NY 10017
J Robert Kerrey director NEW SCHOOL UNIVERSITY, 66 W. 12TH STREET, NEW YORK NY 10036
Josh Wolfe 10 percent owner C/O LUX HEALTH TECH ACQUISITION CORP., 920 BROADWAY, 11TH FLOOR, NEW YORK NY 10010
Bijan Salehizadeh director C/O NAVIMED CAPITAL, 1333 H STREET NW, SUITE 400 WEST, WASHINGTON DC 20005
Segolene Scarborough officer: CFO and Treasurer C/O LUX HEALTH TECH ACQUISITION CORP., 920 BROADWAY, 11TH FLOOR, NEW YORK NY 10010
Lux Encore Sponsor, Lp 10 percent owner C/O LUX HEALTH TECH ACQUISITION CORP., 920 BROADWAY, 11TH FLOOR, NEW YORK NY 10010
Lux Encore Holdings, Llc 10 percent owner C/O LUX HEALTH TECH ACQUISITION CORP., 920 BROADWAY, 11TH FLOOR, NEW YORK NY 10010

Lux Health Tech Acquisition (Lux Health Tech Acquisition) Headlines